Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Thomas C Heineman"'
Autor:
Edward A. Stadtmauer, Keith M. Sullivan, Mohamed El Idrissi, Bruno Salaun, Aránzazu Alonso Alonso, Charalambos Andreadis, Veli-Jukka Anttila, Adrian JC Bloor, Raewyn Broady, Claudia Cellini, Antonio Cuneo, Alemnew F. Dagnew, Emmanuel Di Paolo, HyeonSeok Eom, Ana Pilar González-Rodríguez, Andrew Grigg, Andreas Guenther, Thomas C. Heineman, Isidro Jarque, Jae-Yong Kwak, Alessandro Lucchesi, Lidia Oostvogels, Marta Polo Zarzuela, Anne E. Schuind, Thomas C. Shea, Ulla Marjatta Sinisalo, Filiz Vural, Lucrecia Yáñez San Segundo, Pierre Zachée, Adriana Bastidas
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 11, Pp 4144-4154 (2021)
Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (pro
Externí odkaz:
https://doaj.org/article/c5297d7339fc47679ada3fceed31e22b
Autor:
Lidia Oostvogels, Thomas C. Heineman, Robert W. Johnson, Myron J. Levin, Janet E. McElhaney, Peter Van den Steen, Toufik Zahaf, Alemnew F. Dagnew, Roman Chlibek, Javier Diez-Domingo, Iris S. Gorfinkel, Caroline Hervé, Shinn-Jang Hwang, Hideyuki Ikematsu, George Kalema, Himal Lal, Shelly A. McNeil, Tomas Mrkvan, Karlis Pauksens, Jan Smetana, Daisuke Watanabe, Lily Yin Weckx, Anthony L. Cunningham
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 12, Pp 2865-2872 (2019)
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to
Externí odkaz:
https://doaj.org/article/2de77cc0739443df82239135c7c026b5
Autor:
Olivier Godeaux, Martina Kovac, Daniel Shu, Katrijn Grupping, Laura Campora, Martine Douha, Thomas C. Heineman, Himal Lal
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 5, Pp 1051-1058 (2017)
This phase III, non-randomized, open-label, multi-center study (NCT01827839) evaluated the immunogenicity and safety of an adjuvanted recombinant subunit herpes zoster (HZ) vaccine (HZ/su) in adults aged ≥ 50 y with prior physician-documented histo
Externí odkaz:
https://doaj.org/article/246034a212a14e5dbbcaae429abe973c
Autor:
Thomas C Heineman, Houra Loghmani, Richard Trauger, Fernando Salvador, Luis Manso, Tomás Pascual, Manel Juan, Aleix Prat, Joaquín Gavilá, Matt Coffey, E Azucena González-Navarro
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Thomas C. Heineman, Scott A. Van Wart, Rose E. Sekulovich, Daniel C. Maneval, Donald E. Mager, Nash Gabrail, Megan Baumgart, Anas M. Fathallah, Charvi Nanavati
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1875-1885 (2021)
Clinical and Translational Science
Clinical and Translational Science
This open‐label, phase Ib study (NCT02346370) assessed the effect of pegvorhyaluronidase alfa (PVHA; PEGPH20) on the plasma pharmacokinetics (PKs) and safety of docetaxel in 15 patients with stage IIIB/IV non‐small cell lung cancer (NSCLC). The d
Autor:
Lucrecia Yáñez San Segundo, Bruno Salaun, Hyeon Seok Eom, Antonio Cuneo, Ana P Gonzalez-Rodriguez, Mohamed El Idrissi, Charalambos Andreadis, Ulla Marjatta Sinisalo, Raewyn Broady, Anne Schuind, Lidia Oostvogels, Andreas Gunther, Alessandro Lucchesi, Aránzazu Alonso Alonso, Thomas C. Heineman, Alemnew F Dagnew, Isidro Jarque, Pierre Zachee, Jae Yong Kwak, Emmanuel Di Paolo, Claudia Cellini, Adriana Bastidas, Adrian Bloor, Veli-Jukka Anttila, Andrew Grigg, Thomas C. Shea, Keith M. Sullivan, Marta Polo Zarzuela, Edward A. Stadtmauer, Filiz Vural
Publikováno v:
Human Vaccines and Immunotherapeutics, vol 17, iss 11
PLAIN LANGUAGE SUMMARY What is the context? After haematopoletic stem cell transplantation, patlents have impaired immunity from conditioning chemotherapy regimens, often exacerbated by underlying diseases, putting them at high risk of developing her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22d3c5eda93786a63075a3a429aa7e29
https://trepo.tuni.fi/handle/10024/134131
https://trepo.tuni.fi/handle/10024/134131
Publikováno v:
Current Opinion in Immunology. 59:42-48
Herpes zoster is common in older and immune suppressed persons due to diminished VZV-specific cellular immunity. A recombinant herpes zoster vaccine (RZV) consisting of a single VZV glycoprotein and an adjuvant system stimulates robust and persistent
Autor:
Olivier Godeaux, David Marrupe Gonzalez, Lidia Oostvogels, Kyung Hae Jung, Marta López-Fauqued, David Farrugia, Bruno Salaun, Thomas C. Heineman, Emmanuel Di Paolo, Constanza Maximiano Alonso, Shelly A. McNeil, Ignacio Delgado Mingorance, Enrique Grande, Belen Rubio-Viqueira, Javier Puente, Laura Campora, Hartmut Kristeleit, Peter Vink, Juan Francisco Rodriguez Moreno, Mohamed El Idrissi, Sarah Lowndes
Publikováno v:
Cancer. 125:1301-1312
Background The adjuvanted recombinant zoster vaccine (RZV) has demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age and 68% efficacy in autologous hematopoietic stem cell transplant recipients ≥18 years of age. We report th
Autor:
Roman Chlibek, José M Bayas, Harry Collins, Maria Luisa Rodriguez de la Pinta, Edouard Ledent, Johann F Mols, Thomas C Heineman
Publikováno v:
The Journal of infectious diseases. 223(2)
Autor:
Manel Juan, Salvador Blanch, Begoña Bermejo, Patricia Villagrasa, Blanca Cantos, Grey A. Wilkinson, F. Salvador, Yann Izarzugaza, Gerard J. Nuovo, A. G. González, Thomas C. Heineman, Juan Miguel Cejalvo, Alejandro Martínez, Luis Manso, Raquel Andrés, Esteban Nogales, Nuria Chic, D. Martinez, Blanca Gonzalez-Farre, Matthew C. Coffey, Xavier Gonzalez, J.M. Alonso, Rafael Villanueva, Pilar Zamora, Joaquín Gavilá, Laia Paré, Mireia Margeli, Aleix Prat, Juan Antonio Guerra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background A previous phase 2 study in metastatic breast cancer demonstrated a statistically significant improvement in overall survival (OS) in patients treated with pelareorep (pela) in combination with paclitaxel (PTX) versus PTX alone.1 Given tha